TELA Bio Forecasts $21.05M Q4 Revenue, Analysts See 343% Upside
TELA Bio is set to report Q4 2025 revenue of $21.05 million and a loss of $0.18 per share, with full-year 2025 revenue forecast at $80.45 million and EPS at –$0.84. Five analysts set a 12-month average target of $3.45, implying 343% upside.
1. Q4 2025 Earnings Outlook
TELA Bio will release Q4 2025 results on March 24, with revenue consensus at $21.05 million and a loss of $0.18 per share. Full-year 2025 forecasts call for $80.45 million in revenue and EPS of –$0.84.
2. Q3 2025 Results
In Q3 ended September 30, 2025, TELA Bio reported $20.69 million in revenue, missing the $21.79 million estimate by 5.04%, while EPS of –$0.19 beat the –$0.20 forecast by 2.56%, and the stock declined by 9.97% on the day of release.
3. Analyst Price Targets and Ratings
Five analysts rate the stock at an average 2.0 (Outperform) and assign a 12-month average price target of $3.45, ranging from $1.25 to $5.00, suggesting 343% upside from current levels.